One of Canada’s largest banks trimmed almost a billion dollars off this year’s forecast for adult-use cannabis sales, mostly due to issues arising from a slow roll-out of regulated stores in key provincial markets as well as shuttered locations because of the COVID-19 pandemic.

CIBC Capital Markets, the investment banking subsidiary of the Canadian Imperial Bank of Commerce, sees recreational cannabis sales hitting 2.5 billion Canadian dollars ($1.8 billion) this year – much lower than its previous CA$3.4 billion estimate.

That is still more than double last year’s CA$1.2 billion in sales.

Its forecast for 2021 was lowered to CA$4.1 billion, down from previous expectations of a CA$5.5 billion market.

“The catalyst for the Canadian cannabis market in 2020 was obvious: a wave of stores in Ontario – and to some extent Quebec and British Columbia – was set to propel the industry,” analyst John Zamporo wrote in a report for clients.

“COVID-19 has now brought about serious doubt as to when this might occur. Even once conditions allow more freedom of movement, it will take time for regulators to work through the backlog of store authorizations. And even then, we suspect some would-be market participants will be skittish on deploying significant capital to open stores.”

The forecast is exclusive of medical sales.

The report notes that “improvements on product breadth, pricing, and availability have driven sales somewhat, but the lack of a more fulsome physical retail presence will limit upside, as consumers continue to show preference for buying in person.”

The CIBC Capital Markets forecast was disclosed in its quarterly review of the cannabis industry.

“Without meaningful store growth, we believe the per capita consumption in Canada will remain below U.S. states with greater store penetration,” the report concludes.

Alberta’s 449 stores still leads Canada by a wide margin. Some 182 stores have opened in British Columbia, while Ontario lags far behind with a little over five-dozen stores authorized.

Ontario’s cannabis regulator is resuming new store authorizations after hitting pausing because of COVID-19.

The CIBC report casts doubt on the longevity of the surge in sales observed after the onset of the pandemic.

Regulated online sales typically capture “less than 10% of total retail sales,” the report points out.

“In other words, if brick and mortar stores are seeing reduced revenues of say 25% – which we believe to be very reasonable, albeit for a short period of time – for overall retail sales to continue to grow, online purveyors would need to grow by more than 10-times to make up for the difference,” it says.

Other factors cited for the lower estimates are:

• Limited product offerings and genetics.
• Marketing restrictions.
• Limited CBD distribution.

The CIBC report knocks cannabis companies for their lack of preparedness for the so-called 2.0 categories – edibles, extracts and topicals.

Several companies, including Canopy Growth, had to delay rolling out infused beverages.

“We have been surprised at the lack of readiness for the launch of derivative products, by both producers and provincial wholesalers. Some industry players publicly touted their ability to serve these products, but finding these items has proven somewhat challenging,” according to the report.

For more of Marijuana Business Daily’s ongoing coverage of the coronavirus pandemic and its effects on the cannabis industry, click here.

Pure CBD Hemp Oil

• Pure CBD Tincture, derived from organic, US-harvested hemp, lab-tested for quality.

• Clinically proven therapeutic effects.

• Relieves anxiety and stress

• Eliminates chronic pain and aches

• Regulates mood and sleep patterns

• Enhances focus and clarity
  
  
  

George Scorsis Aphria
Originally posted on via Cannabis Industry News